X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · Real-Time Price · USD

4.040

+0.010 (0.25%)

At close: Aug 21, 2026, 4:00 PM EDT

4.127

+0.087 (2.15%)

After-hours: Aug 21, 2026, 7:30 PM EDT

X4 Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	195.1	217.05	55.7	99.22	121.72	81.79
Short-Term Investments	12.87	35.95	46.36	15	-	-
Cash & Short-Term Investments	207.97	253	102.06	114.22	121.72	81.79
Cash Growth	230.37%	147.89%	-10.64%	-6.16%	48.82%	3.91%
Accounts Receivable	2.05	0.57	1.07	-	-	-
Other Receivables	-	-	0.64	0.56	1.15	0.75
Receivables	2.05	0.57	1.71	0.56	1.15	0.75
Inventory	5.5	4.48	2.82	-	-	-
Prepaid Expenses	2.76	2.52	5.59	7.05	5.52	5.34
Restricted Cash	0.58	0.8	-	0.25	0.29	-
Other Current Assets	-	0.2	-	-	-	-
Total Current Assets	218.86	261.58	112.18	122.08	128.68	87.88
Property, Plant & Equipment	0.77	1.59	4.84	6.4	8.33	10.22
Goodwill	17.35	17.35	17.35	17.35	17.35	17.35
Other Intangible Assets	13.1	9.25	10	-	-	-
Long-Term Deferred Charges	-	0.5	-	-	-	-
Other Long-Term Assets	2.99	0.19	2.08	1.44	1.23	1.72
Total Assets	253.06	290.46	146.45	147.26	155.59	117.18

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	3.93	5.7	8.62	8.95	7.78	4.28
Accrued Expenses	14.13	18.6	23.01	12.82	11.44	7.85
Current Portion of Long-Term Debt	-	-	-	-	1.32	0.8
Current Portion of Leases	0.47	0.99	1.25	1.1	1.2	1.08
Current Unearned Revenue	0.84	0.46	-	-	-	-
Other Current Liabilities	-	-	-	-	0.59	0.03
Total Current Liabilities	19.37	25.76	32.88	22.86	22.32	14.02
Long-Term Debt	76.76	76.29	75.43	54.57	32.3	33.14
Long-Term Leases	-	-	1.41	2.61	3.6	4.78
Long-Term Unearned Revenue	0.59	0.62	-	-	-	-
Other Long-Term Liabilities	0.89	1.5	14.59	16.12	23.3	0.83
Total Liabilities	97.61	104.17	124.3	96.16	81.54	52.76

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.1	0.09	0.01	0.17	0.12	0.03
Additional Paid-In Capital	786.43	780.86	537.62	528.96	450.79	347.37
Retained Earnings	-630.95	-594.55	-515.36	-477.91	-376.74	-282.87
Comprehensive Income & Other	-0.12	-0.11	-0.12	-0.12	-0.12	-0.12
Total Common Equity	155.45	186.29	22.15	51.1	74.05	64.41
Shareholders' Equity	155.45	186.29	22.15	51.1	74.05	64.41
Total Liabilities & Equity	253.06	290.46	146.45	147.26	155.59	117.18

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	77.22	77.29	78.09	58.28	38.42	39.79
Net Cash (Debt)	130.75	175.71	23.97	55.94	83.3	42
Net Cash Growth	-	632.93%	-57.14%	-32.85%	98.32%	4.33%
Net Cash Per Share	1.28	4.15	3.58	9.44	39.34	48.94
Filing Date Shares Outstanding	99.15	90.92	5.79	5.6	4.07	1.03
Total Common Shares Outstanding	96.11	90.91	5.7	5.58	4.06	0.94
Working Capital	199.49	235.82	79.3	99.21	106.35	73.86
Book Value Per Share	1.62	2.05	3.89	9.16	18.26	68.70
Tangible Book Value	125	159.69	-5.2	33.75	56.7	47.06
Tangible Book Value Per Share	1.30	1.76	-0.91	6.05	13.98	50.19
Machinery	1.22	1.19	2.43	2.11	2.08	1.98
Leasehold Improvements	0.23	0.23	0.23	0.23	0.23	0.23

SEC Filings: 10-K · 10-Q